MTHFR C677T polymorphism contributes to prostate cancer risk among Caucasians: A meta-analysis of 3511 cases and 2762 controls

European Journal of Cancer

Volumn 45, Issue 8, 2009, Pages 1443-1449

  Bai, Jian Ling ^a   Zheng, Ming Hua ^b   Xia, Xian ^c   Ter Minassian, Monica ^d   Chen, Yong Ping ^b   Chen, Feng ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Meta analysis; MTHFR polymorphism; Prostate cancer

Indexed keywords

METHYLENETETRAHYDROFOLIC ACID;

ALLELE; ARTICLE; CANCER RISK; CAUCASIAN; COMPARATIVE STUDY; GENE; GENETIC MODEL; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HOMOZYGOTE; HUMAN; META ANALYSIS; MUTANT; PRIORITY JOURNAL; PROSTATE CANCER; PROTECTION;

CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOTYPE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS;

EID: 65249091990     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.01.020     Document Type: Article

References (28)

1. Ueland P.M., Hustad S., Schneede J., et al. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 22 (2001) 195-201
2. Frosst P., Blom H.J., Milos R., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10 (1995) 111-113
3. van der Put N.M., Gabreels F., Stevens E.M., et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?. Am J Hum Genet 62 (1998) 1044-1051
4. Weisberg I.S., Jacques P.F., Selhub J., et al. The 1298A-C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. Atherosclerosis 156 (2001) 409-415
5. Nelson W.G., De Marzo A.M., and Isaacs W.B. Prostate cancer. New Engl J Med 349 (2003) 366-381
6. Lee W.H., Isaacs W.B., Bova G.S., et al. CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: a new prostate cancer biomarker. Cancer Epidemiol Biomarkers Prev 6 (1997) 443-450
7. Fenech M. The role of folic acid and Vitamin B12 in genomic stability of human cells. Mutat Res 475 (2001) 57-67
8. Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet 19 (1955) 251-253
9. Lau J., Ioannidis J.P., and Schmid C.H. Quantitative synthesis in systematic reviews. Ann Intern Med 127 (1997) 820-826
10. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188
11. Aurelio T. Assessing the influence of a single study in the meta-anyalysis estimate. Stata Tech Bull 8 (1999) 15-17
12. Egger M., Smith G.D., and Altman D.G. Systematic reviews in health care: meta-analysis in context. 2nd ed. (2001), BMJ, London
13. Egger M., Davey Smith G., Schneider M., et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997) 629-634
14. Kimura F., Franke K.H., Steinhoff C., et al. Methyl group metabolism gene polymorphisms and susceptibility to prostatic carcinoma. Prostate 45 (2000) 225-231
15. Cicek M.S., Nock N.L., Li L., et al. Relationship between methylenetetrahydrofolate reductase C677T and A1298C genotypes and haplotypes and prostate cancer risk and aggressiveness. Cancer Epidemiol Biomarkers Prev 13 (2004) 1331-1336
16. Singal R., Ferdinand L., Das P.M., et al. Polymorphisms in the methylenetetrahydrofolate reductase gene and prostate cancer risk. Int J Oncol 25 (2004) 1465-1471
17. Van Guelpen B.R., Wiren S.M., Bergh A.R., et al. Polymorphisms of methylenetetrahydrofolate reductase and the risk of prostate cancer: a nested case-control study. Eur J Cancer Prev 15 (2006) 46-50
18. Marchal C., Redondo M., Reyes-Engel A., et al. Association between polymorphisms of folate-metabolizing enzymes and risk of prostate cancer. Eur J Surg Oncol (2007)
19. Johansson M., Van Guelpen B., Hultdin J., et al. The MTHFR 677C-T polymorphism and risk of prostate cancer: results from the CAPS study. Cancer Causes Control 18 (2007) 1169-1174
20. Reljic A., Simundic A.M., Topic E., et al. The methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and cancer risk: the Croatian case-control study. Clin Biochem 40 (2007) 981-985
21. Chen J., Giovannucci E., Hankinson S.E., et al. A prospective study of methylenetetrahydrofolate reductase and methionine synthase gene polymorphisms, and risk of colorectal adenoma. Carcinogenesis 19 (1998) 2129-2132
22. Pereira T.V., Rudnicki M., Pereira A.C., et al. 5, 10-Methylenetetrahydrofolate reductase polymorphisms and acute lymphoblastic leukemia risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15 (2006) 1956-1963
23. Wiemels J.L., Smith R.N., Taylor G.M., et al. Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia. Proc Natl Acad Sci USA 98 (2001) 4004-4009
24. Matsuo K., Suzuki R., Hamajima N., et al. Association between polymorphisms of folate- and methionine-metabolizing enzymes and susceptibility to malignant lymphoma. Blood 97 (2001) 3205-3209
25. Heijmans B.T., Boer J.M., Suchiman H.E., et al. A common variant of the methylenetetrahydrofolate reductase gene (1p36) is associated with an increased risk of cancer. Cancer Res 63 (2003) 1249-1253
26. Hubner R.A., and Houlston R.S. MTHFR C677T and colorectal cancer risk: A meta-analysis of 25 populations. Int J Cancer 120 (2007) 1027-1035
27. Pavillard V., Drbal A.A., Swaine D.J., et al. Analysis of cell-cycle kinetics and sulfur amino acid metabolism in methionine-dependent tumor cell lines; the effect of homocysteine supplementation. Biochem Pharmacol 67 (2004) 1587-1599
28. Botto L.D., and Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol 151 (2000) 862-877